Monthly Archives: November 2023

Cancer and neoplasms

Texture and color enhancement imaging improves the visibility of gastric neoplasms: clinical trial with image catalogue assessment using conventional and newly developed endoscopes

Posted on by yun
12
Nov

Patients and study design This was a single-center, prospective trial. We prospectively enrolled patients who were diagnosed with gastric neoplasms (including adenoma and adenocarcinoma) through endoscopic and histological diagnosis, and who were referred to our hospital for treatment. Patients were enrolled as consecutive cases in this study to eliminate selection bias. Written informed consent was […]

Continue reading →
Congenital disorders

Early predictors for maltreatment-related injuries in infancy and long-term mortality: a population-based study

Posted on by yun
12
Nov

Hillis S, Mercy J, Amobi A, Kress H. Global prevalence of past-year Violence against children: a systematic review and minimum estimates. Pediatrics. 2016;137(3). Kim H, Drake B. Cumulative prevalence of onset and recurrence of child maltreatment reports. J Am Acad Child Adolesc Psychiatry. 2019;58(12):1175–83. Article  PubMed  Google Scholar  Fang X, Brown DS, Florence CS, Mercy […]

Continue reading →
Blood

Companies Devise New Ways to Smuggle Drugs Across the Blood-Brain Barrier

Posted on by yun
12
Nov

Pictured: abstract bokeh optical light/iStock, Oleksandr Bushko The blood-brain barrier: It’s neuroscience’s next frontier, and a presentation on Roche’s trontinemab at the Clinical Trials on Alzheimer’s Disease conference last month sparked new optimism that researchers might be getting close to breaking through it.    A diffusion barrier, the blood-brain barrier (BBB) prevents about 98% of small molecule […]

Continue reading →
Cancer and neoplasms

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Posted on by yun
12
Nov

Abstract Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult […]

Continue reading →
Infection

Fatty acid production and its impact on severe and fatal respiratory viral infections

Posted on by yun
12
Nov

Add to my calendar 16/11/2023 12:00 pm 16/11/2023 1:00 pm Australia/Melbourne Fatty acid production and its impact on severe and fatal respiratory viral infections Doherty Institute Auditorium, 792 Elizabeth Street DD/MM/YYYY At this event Dr Brendan Chua, Research Fellow from the Department of Microbiology and Immunology, University of Melbourne, will present Fatty acid production and its […]

Continue reading →
Cancer and neoplasms

Case series of ovarian neuroendocrine carcinoma: overview of clinicopathological features

Posted on by yun
12
Nov

The pathogenesis of primary O-NECs is not well understood. These tumors are primarily classified into three histological types: SCCs (hypercalcemic, pulmonary types), carcinoid (insular, trabecular, goiter, mucinous carcinoid, mixed types), and large cell NEC [1]. At present, there is limited clinical understanding regarding the incidence, histogenesis, treatment, and prognosis of this disease. In this report, […]

Continue reading →
Cardiovascular

Cardiovascular events and venous thromboembolism after primary malignant or non-malignant brain tumour diagnosis: a population matched cohort study in Wales (United Kingdom)

Posted on by yun
12
Nov

Participant characteristics This study included 6800 patients with primary brain tumour diagnosed in Wales 2000–2014 and their 33,785 age-, sex- and GP practice-matched controls. Cohort selection is presented in Fig. 1. The total follow-up time for brain tumour patients and their controls were 32,453.9 person-year (median 3.5 years; interquartile range [IQR] 3.5–10.1) and 247,142.1 person-year (median 6.6 years; […]

Continue reading →
Cancer and neoplasms

Decoding γδ T cell anticancer therapies: integrating CRISPR screens with tumor organoids

Posted on by yun

In a recent publication in Nature,1 Mamedov and colleagues identified pathways that modulate γδ T cell killing and BTN3A cellular expression through integrating genome-wide CRISPR screens and tumor organoid culture, deepening our comprehension of γδ T cell stress surveillance and proposing novel pathways to boost γδ T cell’s anticancer functions (Fig. 1). Fig. 1 Vγ9Vδ2 […]

Continue reading →
Blood

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Posted on by yun

SINGAPORE, Nov. 12, 2023 /PRNewswire/ — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths […]

Continue reading →